Navigation Links
Abilify Has Made Strong Gains in Patient Share Across All Lines of Therapy Since Last Year's Analysis of Prescribing Trends in Schizophrenia

WALTHAM, Mass., July 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the patient share of Bristol-Myers Squibb/Otsuka's Abilify has grown in the first three lines of therapy since the 2008 analysis of prescribing trends in newly diagnosed schizophrenia patients. Abilify is second to risperidone (Janssen's Risperdal, generics) in first and second lines of therapy and leads other atypicals in the third line.

"Abilify's first-line patient share grew from 4.2 percent in our 2008 analysis to 14.6 percent in the current dataset. Pfizer's Geodon also grew substantially compared with our 2008 analysis whereas both Eli Lilly's Zyprexa and AstraZeneca's Seroquel lost first-line patient share," stated Nicole Westphal, Ph.D., analyst at Decision Resources. "These data suggest that Abilify and Geodon's better penetration of first-line therapy came at the expense of others in the class and we attribute Zyprexa's and Seroquel's declining use across early lines of therapy to concerns about their metabolic side effects."

The new Treatment Algorithms in Schizophrenia report also finds that surveyed psychiatrists will remain focused on an agent's metabolic or weight gain side effects when treating current and newly diagnosed patients. The majority of surveyed psychiatrists will switch patients from atypicals with unfavorable metabolic side-effect profiles to those with more favorable profiles or increasingly consider weight gain and metabolic side-effect profiles when choosing an antipsychotic in the first-line.

By combining patient-level claims data with physician survey data, this report can be used to build patient-flow models and analyze the assumptions driving these models.

Patient-flow analysis for Janssen's Invega shows that only three percent of all users took the drug as a first-line agent. However, surveyed psychiatrists expect to substantially increase their first- and second-line prescriptions for the drug. As Invega continues to experience increased uptake in early lines of therapy, surveyed psychiatrists indicate that risperidone and Zyprexa will lose the most share. These data indicate that marketers of current and emerging atypical antipsychotics will need to position themselves against Invega's growing use as an early-line agent.

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from IMS Lifelink: Health Plans Claims database to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Gisselle Morales                             Elizabeth Marshall
    Decision Resources                           Decision Resources, Inc.
    781-296-2691                                 781-296-2563            

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Otsuka to Pay More Than $4 Million to Resolve Off-Label Marketing Allegations Involving Abilify
2. ABILIFY approved for acute treatment of bipolar I disorder in patients 10 to 17 years old
3. FDA approves ABILIFY(R) (aripiprazole) as the first medication for add-on treatment of MDD
4. ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration
5. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia
6. US FDA approves ABILIFY for adolescent patients with schizophrenia
7. Quest Diagnostics Reports Strong Performance in Second Quarter 2009
8. Abbott Reports Strong Second Quarter Results; Confirms Double-Digit Earnings Growth Outlook for 2009
9. Minority Business Accelerator 2.5+ Client Strong Tool Lands Multimillion Dollar Deal With GE Healthcare
10. TeamPraxis Finishes Strong First Year of National Sales
11. Abatement Technologies Sees Strong Demand as Hospitals Prepare for Stage 6 Flu Pandemic
Post Your Comments:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... ... 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s ... setting the bar too high can result in disappointment, perhaps even self-loathing. However, those ... goal. , Research from reveals that behind the tendency to ...
(Date:6/24/2016)... ... , ... Marcy was in a crisis. Her son James, eight, was out of control. Prone ... physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If ... at my other children and say he was going to kill them. If we ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016 Dublin ... addition of the " Global Markets for Spectroscopy ... This report focuses on the ... review, including its applications in various applications. The report ... includes three main industries: pharmaceutical and biotechnology, food and ...
(Date:6/24/2016)... Research and Markets has announced the ... Tests" report to their offering. ... The World Market for Companion Diagnostics covers the ... analysis in the report includes the following: ... Kits) by Region (N. America, EU, ROW), 2015-2020 , ...
(Date:6/23/2016)... HOUSTON , June 23, 2016  MedSource ... platform as its e-clinical software solution of choice.  ... the best possible value to their clients by ... nowEDC.  The preferred relationship establishes nowEDC as the ... pricing for MedSource,s full-service clients.  "nowEDC has long ...
Breaking Medicine Technology: